Send me real-time posts from this site at my email

Gilead Sciences Stops Accepting Emergency-Use Applications for Remdesivir

The coronavirus pandemic has overtaxed an expanded-use system that just wasn't designed to handle the volume of requests it's getting right now for remdesivir, an experimental antiviral treatment from Gilead Sciences (NASDAQ: GILD).

The overwhelming surge in demand has forced the company to stop accepting new requests from individuals with COVID-19 who want to try the treatment.

Image source: Getty Images.

The FDA can allow the use of an experimental treatment in cases when patients aren't eligible to enter an ongoing clinical trial of the drug in question. But getting permission to try such an unproven treatment is an involved process that requires consent from an informed patient and lots of paperwork from their physician and Gilead Sciences just to get started.

Given that no treatments have yet been proven to be effective against SARS-CoV-2 in proper clinical trials, there's enormous interest in those that appear promising, which remdesivir does.

So Gilead Sciences has been meeting as many of these requests for use of remdesivir as possible, but they have piled up beyond the system's ability to process. For each request, an investigational review board (IRB) needs to review the physician's treatment plan and ensure the patient knows what they're getting into. If the IRB approval on an individual application, it still needs to be reviewed and approved by the FDA before treatment can begin.

In recent weeks, the number of individual requests for permission to use remdesivir has grown so rapidly that Gilead Sciences now expects it will have pivotal trial data in hand -- and possibly an FDA approval for the drug as a COVID-19 treatment -- before the IRB and FDA can work through the current backlog of expanded-use applications.

In late February, Gilead Sciences began a pair of phase 3 clinical trials in the U.S. to measure the safety and efficacy of remdesivir in adults with COVID-19. There are also trials underway in China's Hubei province that could provide results in April.

10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of March 18, 2020

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue